The authors investigated the association between overweight at the time of or soon after cancer diagnosis and survival in a cohort of 1,455 breast cancer patients aged 25-64 years. The patients were recruited into the Shanghai Breast Cancer Study (Shanghai, China), a population-based case-control study, between August 1996 and March 1998. The median follow-up time for this cohort was 5.1 years (1996)(1997)(1998)(1999)(2000)(2001)(2002) after breast cancer diagnosis, and 240 deaths were identified. Being overweight at cancer diagnosis or soon afterward, as measured by body mass index (BMI; weight (kg)/height (m)
Research has suggested that obesity is associated with increased risk of breast cancer among postmenopausal women but is unrelated or inversely related to risk among premenopausal women (1) . The association between body size and breast cancer prognosis has been investigated in a number of studies, mainly studies conducted in Western countries . Increased body weight or body mass index (BMI; weight (kg)/height (m) 2 ) has been found to be inversely associated with overall survival and disease-free survival in both pre-and postmenopausal women, although the evidence is not entirely consistent (28) . The effect of body fat distribution on breast cancer prognosis has also been examined (13, 15, 23, 29) . Elevated waist:hip ratio was associated with breast cancer mortality among postmenopausal women in one study (23) but not in another (13) .
It has been suggested that Asian Americans have better survival rates for breast cancer than non-Hispanic Whites in the United States (30) , and Asian women also typically have a low prevalence of overweight/obesity. However, the relation between overweight/obesity and survival after breast cancer diagnosis in Asians has only been evaluated in two small-scale studies (6, 31) . In this report, we describe the association between being overweight at or soon after breast cancer diagnosis and breast cancer survival in a cohort of breast cancer patients recruited into the Shanghai Breast Cancer Study, a population-based case-control study.
MATERIALS AND METHODS

Subjects and study design
Through a rapid case-ascertainment system supplemented by the population-based Shanghai Cancer Registry, we identified 1,602 women aged 25-64 years who were diagnosed with primary breast cancer in Shanghai, China, between August 1996 and March 1998. Of these women, 1,459 (91.1 percent) completed an in-person interview and were included in the Shanghai Breast Cancer Study as cases. Reasons for nonparticipation included refusal (109 cases; 6.8 percent), death prior to interview (17 cases; 1.1 percent), and inability to locate potential subjects (17 cases; 1.1 percent).
Weight, waist and hip circumferences, and sitting and standing heights were measured in all study participants by trained interviewers according to a standard protocol. Two measurements were taken for each variable, with a tolerance of less than 1 cm for height and waist and hip circumferences and a tolerance of 1 kg for weight. A third measurement was taken if the difference between the first two was larger than the tolerances stated above. The averages of the two closest measurements were used to calculate BMI and waist:hip ratio.
Two senior pathologists independently reviewed pathologic slides to confirm the initial cancer diagnoses. Information on cancer diagnosis, cancer stage (as measured by tumor-node-metastasis (TNM) stage), cancer treatment, and estrogen receptor (ER)/progesterone receptor (PR) status was abstracted from medical charts using a standard protocol.
Patients were followed through January 2003 with a combination of active follow-up and record linkage to death certificates kept by the Vital Statistics Unit of the Shanghai Municipal Center for Disease Control and Prevention. Of the 1,459 patients included in the original study, 1,290 (88.4 percent) patients or next of kin were successfully contacted either in person (n ¼ 1,241; 85.0 percent) or by telephone (n ¼ 49; 3.4 percent) between March 2000 and December 2002. Two hundred (15.5 percent) of the 1,290 patients were deceased. Through interviews with patients or (for deceased patients) next of kin, we obtained information on disease progress, recurrence, and (if deceased) cause of death. Survival status for the remaining 169 participants who could not be contacted through a home visit or by telephone was established in June 2003 by linkage to the death registry. Forty deaths were identified with this method, and information on the date and cause of death was obtained. There were 126 subjects for whom no match in the death registry could be found, and they were assumed to be still living. We assigned December 31, 2002-6 months prior to our search of the death registry-as the censoring date for these subjects in order to allow for a possible delay of entry of death certificates into the registry. Four subjects had insufficient information for record linkage and were excluded from the current analysis. This study was approved by the institutional review boards of all participating institutions.
Statistical analysis
The primary outcomes for this study were overall survival and disease-free survival. The endpoint for the analysis of overall survival was any death, and for the analysis of disease-free survival it was cancer recurrence/metastasis or death related to breast cancer. Survival time was calculated as the time from cancer diagnosis to the endpoints of the study, censoring at the date of last contact or noncancer death (for disease-free survival only). We used the KaplanMeier method to compute 5-year survival and 5-year disease-free survival rates, and we applied the log-rank test to evaluate the differences in survival across different strata. Quartile distributions were used to categorize data on BMI, waist:hip ratio, and waist circumference. We also constructed BMI and waist:hip ratio categories using the classification for Asians recommended by the World Health Organization (32) . We checked the proportional hazards assumption through log plots. We applied the Cox regression model to evaluate the effect of BMI and waist:hip ratio on overall survival with adjustment for age at diagnosis (treated as a continuous variable) and other known prognostic factors for breast cancer. We further evaluated the associations of BMI and waist:hip ratio with the study outcomes by stratifying on TNM stage and menopausal status. Menopausal status was defined as no menstruation during the past 12 months, excluding those lapses caused by pregnancy or breastfeeding. All statistical tests were based on twosided probability. Statistical analyses were conducted using SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
During the study period, 240 of the 1,455 patients were found to be deceased, with an overall 5-year survival rate of 84.0 percent. Table 1 presents the associations of selected demographic factors and known breast cancer prognostic factors with overall 5-year survival rate. Women with breast cancer diagnosed at a younger age (<40 years) and during the perimenopausal period (ages 50-59 years) had a lower 5-year survival rate than women in other age groups. As expected, TNM stage was an important prognostic factor for overall survival. The majority of patients (99 percent) underwent surgery, and as part of their regular treatment for breast cancer, 94 percent of patients received adjuvant chemotherapy. Traditional Chinese medicine was also commonly used; 63.0 percent of patients received both adjuvant chemotherapy and traditional Chinese medicine. We did not have specific information on chemotherapy for each patient in this study; however, on the basis of data from an ongoing study of 2,245 breast cancer survivors in Shanghai, we estimated that 92 percent of the patients received adjuvant chemotherapy. Among these persons, 84 percent received 5-fluorouracil, 89 percent received cyclophosphamide, and 30 percent received methotrexate as part of their chemotherapy. Having received radiotherapy was associated with a lower overall survival rate; this may have been related to a late stage of disease at diagnosis. Information on tamoxifen use was obtained during the follow-up survey. As expected, patients treated with tamoxifen had a more favorable prognosis than nonusers and those without information. ER/PR status was not significantly associated with survival in this population. However, information on ER/PR status was missing for approximately 30 percent of subjects.
BMI at the time of interview was inversely associated with overall survival and disease-free survival (table 2) . Five-year overall survival rates were 86.5 percent, 83.8 percent, and 80.1 percent for patients with BMIs of <23.0, 23.0-24.9, and 25.0, respectively (p ¼ 0.02); the corresponding 5-year disease-free survival rates were 81.9 percent, 78.1 percent, and 76.6 percent (p ¼ 0.05). Survival curves by BMI are shown in figures 1 and 2. Of the 240 deceased patients in our study, 218 (90.8 percent) died of breast cancer. We also conducted survival analyses for breast-cancerspecific mortality and found that the association between breast-cancer-specific mortality and BMI was similar to that reported for overall survival (data not shown). Waist circumference was significantly related to 5-year overall survival but not to disease-free survival. There were no significant differences in 5-year overall survival rates and disease-free survival rates across categories of waist:hip ratio. Table 3 shows the associations of BMI, waist:hip ratio, and waist circumference with overall and disease-free survival after adjustment for age at diagnosis and other known prognostic factors for breast cancer. Patients in the highest quartile of BMI had significantly poorer overall survival and disease-free survival than patients in the lowest quartile (adjusted hazard ratio (HR) ¼ 1.4 (95 percent confidence interval (CI): 1.0, 2.0) and adjusted HR ¼ 1.3 (95 percent CI: 1.0, 1.8), respectively). Similarly, the adjusted hazard ratios associated with a BMI greater than or equal to 25 were 1.3 (95 percent CI: 1.0, 1.8) and 1.3 (95 percent CI: 1.0, 1.7) for overall and disease-free survival, respectively, in comparison with subjects of normal weight (BMI < 23.0). We found neither waist:hip ratio nor waist circumference to be associated with overall survival or disease-free survival in the multivariate analyses.
The median interval between breast cancer diagnosis and interview for cases was 67 days (25th-75th percentiles, , and this interval did not appear to differ between obese and nonobese breast cancer patients. Additional adjustment for interval between disease diagnosis and interview, usual physical activity, and total energy intake 5 years prior to diagnosis did not appreciably change the risk estimates presented in table 3 (data not shown).
Postmenopausal women had poorer overall and diseasefree survival rates than premenopausal women (adjusted HR ¼ 1.9 (95 percent CI: 1.3, 2.9) and adjusted HR ¼ 2.1 (95 percent CI: 1.5, 3.1), respectively). Among postmenopausal women, BMI was found to be associated with increased, though not significantly increased, risks of death (HR ¼ 1. We also conducted analyses stratified on TNM stage and ER/PR status. Eighty-two percent of study subjects had 
DISCUSSION
In this population-based cohort study of 1,455 patients with primary breast cancer, we found that being overweight (BMI 25.0) at or soon after cancer diagnosis was inversely related to both overall survival and disease-free survival. This association persisted after adjustment for known breast cancer prognostic factors, including age at diagnosis, education, TNM stage, ER/PR status, chemotherapy, radiotherapy, and tamoxifen treatment. We found no association between waist:hip ratio and breast cancer survival.
In Caucasian populations, obesity at the time of breast cancer diagnosis has been reported to be associated with poorer survival and an increased likelihood of recurrence, though not all studies investigating this relation have found such an association (2-5, 7-12, 14-22, 24-27) . It is known that the body composition profile of Asian populations differs from that of Caucasian and African-American populations. To our knowledge, only two epidemiologic studies have examined the relation between breast cancer survival and obesity in Asian populations (6, 31) . Both involved hospital-based patient cohorts with small sample sizes. Among 593 breast cancer cases, Kimura (31) found no significant difference in the 5-year survival rate, but a significant decrease in the 10-year survival rate was detected between the obese group and the lean group, especially among postmenopausal women. After follow-up of 213 breast cancer patients, Kyogoku et al. (6) reported that BMI measured 1-3 months after surgery was positively related to increased risk of mortality (p trend < 0.01) after adjustment for other prognostic factors and potential confounders. Our results are consistent with those of some previous studies conducted in Caucasian or Asian populations (5-9, 12, 15-19, 21, 20, 27) , but they disagree with the results of other studies (4, 10, 11, 13, 14, 20, 25, 26, 28, 30) . Several mechanisms could account for these observations. Obesity has been found to be associated with a more advanced tumor stage and/or greater lymph node involvement at diagnosis (33) ; the obesity-survival association might reflect the effect of advanced stage at cancer diagnosis. BMI was related to stage of disease at diagnosis in our study population. However, our study and other studies in which the majority of subjects were early-stage breast cancer patients found a positive association between BMI and survival (24, 34) . Further analysis stratified by disease stage in our study showed that being overweight was adversely related to survival among patients with early-stage breast cancer. These results suggest that late stage at cancer diagnosis among overweight women may not be the sole explanation for the observed association between weight and survival.
Another possible explanation is the high concentrations of estrone, estradiol, and testosterone in overweight and obese breast cancer patients stemming from the conversion of androstenedione in adipose tissue. Obesity has also been shown to be related to lower levels of sex hormone-binding globulin, resulting in higher levels of free estradiol and free testosterone (35, 36) . Therefore, estrogen-sensitive tissues in overweight/obese women are subject to higher estrogen stimulation, which may lead to more rapid growth of malignant cells or may promote metastases. Since adipose tissue is the primary source of circulating estrogen in postmenopausal women, estrogen production is directly correlated with body weight after menopause. Thus, it is possible that overweight/obesity may have a stronger effect on survival among postmenopausal patients. Although the 95 percent confidence interval for the hazard ratio included the null value, analyses stratified by menopausal status in our study supported this hypothesis, which is consistent with some previous studies (18, 21) . In addition, adipose tissue produces a group of growth factors, cytokines, and adipocytokines (including leptin, tumor necrosis factor-a, interleukin-6, heparin-binding epidermal growth factor, vascular endothelial growth factor, and hepatocyte growth factor), most of which can stimulate angiogenesis and promote tumor growth and metastasis (37) . A number of adipocytokines also play important roles in the modulation of insulin, which has been found to correlate with breast cancer prognosis (37, 38) .
Higher waist:hip ratio, a marker of hyperinsulinemia, represents greater abdominal fat distribution. Results from previous studies on waist:hip ratio and breast cancer prognosis have been limited and inconsistent (13, 23, 29, 39) . We failed to find an independent association between body fat distribution and breast cancer survival among either premenopausal women or postmenopausal women in our population.
Strengths of our study include the population-based patient cohort, the high response and follow-up rates, the professional measurement of anthropometric factors, and the detailed information on cancer characteristics and treatments. Additionally, the median length of follow-up was 5.1 years (25th-75th percentiles, 4.6-5.6), which provided relatively good statistical power. However, there are a few limitations that should be considered when evaluating our results. The majority of women in this study received adjuvant chemotherapy as part of their regular treatment for breast cancer. However, specific information on chemotherapy and the duration of chemotherapy was not available for all patients in this study, which limited our ability to examine the effect of potential interaction between overweight and chemotherapy on disease prognosis. On the basis of our ongoing study of breast cancer survival in Shanghai, we found that 95.4 percent of breast cancer patients completed their chemotherapy within 6 months after cancer diagnosis, and the duration of treatment was not related to BMI at cancer diagnosis. In several studies, excessive weight and weight gain after diagnosis of breast cancer have been suggested to reduce overall and/or disease-free survival and to increase rates of recurrence and relapse (40) (41) (42) . However, information on weight changes after cancer treatment was not available for our study subjects, which limited our ability to evaluate the association between weight changes after diagnosis and breast cancer survival. The self-reported information on disease relapse and cause of death may have been subject to misclassification bias. Such misclassification is likely to have been nondifferential and to have biased the results towards the null. As we noted above, information regarding ER/PR status was abstracted from hospital records and was missing for approximately 30 percent of study subjects, which compromised our ability to evaluate associations of obesity with breast cancer survival by ER/PR status. Lastly, the lack of information on tamoxifen use for a sizable number of subjects, particularly those who died before the follow-up survey, hampered our ability to evaluate the joint effect of obesity and tamoxifen use on breast cancer survival.
In summary, we found that being overweight at or soon after diagnosis of breast cancer was related to lower rates of overall survival and disease-free survival. Our results, in conjunction with those of other studies, support the idea that interventions directed at weight control may have a substantial effect not only on breast cancer incidence but also on breast cancer survival.
